BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
2 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
3 Li L, Liang D, Guo W, Tang D, Zeng Y. Antibody‐invertase Cross‐linkage Nanoparticles: A New Signal Tag for Point‐of‐Care Immunoassay of Alpha‐fetoprotein for Hepatocellular Carcinoma with Personal Glucometer. Electroanalysis 2022;34:246-51. [DOI: 10.1002/elan.202100212] [Reference Citation Analysis]
4 Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35109664 DOI: 10.2217/fon-2021-0905] [Reference Citation Analysis]
5 Bekric D, Ocker M, Mayr C, Stintzing S, Ritter M, Kiesslich T, Neureiter D. Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers (Basel) 2022;14:1826. [PMID: 35406596 DOI: 10.3390/cancers14071826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]